［1］GRUENBAUM Y,CEDAR H,RAZIN A.Substrate and sequence specificity of a eukaryotic DNA methylase［J］.Nature,1982,295(5850):620-622.
［2］BEERMAN I,ROSSI DJ.Epigenetic regulation of hematopoietic stem cell aging［J］.Exp Cell Res,2014,329(2):192-199.
［3］YANG L,RAU R,GOODELL MA.DNMT3A in haematological malignancies［J］.Nat Rev Cancer,2015,15(3):152-165.
［4］HOLLENBACH PW,NGUYEN AN,BRADY H,et al.A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines［J］.PLoS One,2010,5(2):e9001.
［5］LAGADINOU ED,SACH A,CALLAHAN K,et al.BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells［J］.Cell Stem Cell,2013,12(3):329-341.
［6］SOUERS AJ,LEVERSON JD,BOGHAERT ER,et al.ABT-199,a potent and selective BCL-2 inhibitor,achieves antitumor activity while sparing platelets［J］.Nat Med,2013,19(2):202-208.
［7］LEVERSON JD,SAMPATH D,SOUERS AJ,et al.Found in translation:How preclinical research is guiding the clinical development of the BCL2-selective inhibitor venetoclax［J］.Cancer Discov,2017,7(12):1376-1393.
［8］LEVER JR,FERGASON-CANTRELL EA.Allosteric modulation of sigma receptors by BH3 mimetics ABT-737,ABT-263 (Navitoclax) and ABT-199 (Venetoclax)［J］.Pharmacol Res,2019,142:87-100.
［9］POLLYEA DA,STEVENS BM,JONES CL,et al.Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia［J］.Nat Med,2018,24(12):1859-1866.
［10］JONES CL,STEVENS BM,D'ALESSANDRO A,et al.Inhibition of amino acid metabolism selectively targets human leukemia stem cells［J］.Cancer Cell,2019,35(2):333-335.
［11］BOGENBERGER JM,DELMAN D,HANSEN N,et al.Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies［J］.Leuk Lymphoma,2015,56(1):226-229.
［12］SALIBA AN,JOHN AJ,KAUFMANN SH.Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia［J］.Cancer Drug Resist,2021,4:125-142.
［13］DOMBRET H,SEYMOUR JF,BUTRYM A,et al.International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts［J］.Blood,2015,126(3):291-299.
［14］MEI M,ALDOSS I,MARCUCCI G,et al.Hypomethylating agents in combination with venetoclax for acute myeloid leukemia:Update on clinical trial data and practical considerations for use［J］.Am J Hematol,2019,94(3):358-362.
［15］RICHARD-CARPENTIER G,DINARDO CD.Venetoclax for the treatment of newly diagnosed acute myeloid leukemia in patients who are ineligible for intensive chemotherapy［J］.Ther Adv Hematol,2019,10:2040620719882822.
［16］DINARDO CD,JONAS BA,PULLARKAT V,et al.Azacitidine and venetoclax in previously untreated acute myeloid leukemia［J］.N Engl J Med,2020,383(7):617-629.
［17］RAM R,AMIT O,ZUCKERMAN T,et al.Venetoclax in patients with acute myeloid leukemia refractory to hypomethylating agents-a multicenter historical prospective study［J］.Ann Hematol,2019,98(8):1927-1932.
［18］DINARDO CD,PRATZ K,PULLARKAT V,et al.Venetoclax combined with decitabine or azacitidine in treatment-naive,elderly patients with acute myeloid leukemia［J］.Blood,2019,133(1):7-17.
［19］ALDOSS I,YANG D,ARIBI A,et al.Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia［J］.Haematologica,2018,103(9):e404-e407.
［20］GERDS AT,DEEG HJ.Transplantation for myelodysplastic syndrome in the era of hypomethylating agents［J］.Curr Opin Hematol,2012,19(2):71-75.
［21］PASVOLSKY O,SHIMONY S,RAM R,et al.Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax:a multicenter retrospective study［J］.Ann Hematol,2022,101(2):379-387.
［22］WINTERS AC,BOSMA G,ABBOTT D,et al.Outcomes are similar after allogeneic hematopoietic stem cell transplant for newly diagnosed acute myeloid leukemia patients who received venetoclax+azacitidine versus intensive chemotherapy［J］.Transplant Cell Ther,2022，28(10):694.e1-694.e9.
［23］POLLYEA DA,WINTERS A,MCMAHON C,et al.Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60［J］.Bone Marrow Transplant,2022,57(2):160-166.
［24］SALHOTRA A,TSAI NC,ZHANG J,et al.Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia［J］.Br J Haematol,2022,196(6):e71-e74.
［25］BOSE P,VACHHANI P,CORTES JE.Treatment of relapsed/refractory acute myeloid leukemia［J］.Curr Treat Options Oncol,2017,18(3):17.
［26］DINARDO CD,LACHOWIEZ CA,TAKAHASHI K,et al.Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia［J］.J Clin Oncol,2021,39(25):2768-2778.
［27］SANDHU KS,DADWAL S,YANG D,et al.Outcome of allogeneic hematopoietic cell transplantation after venetoclax and hypomethylating agent therapy for acute myelogenous leukemia［J］.Biol Blood Marrow Transplant,2020,26(12):e322-e327.
［28］KENNEDY VE,HUI G,AZENKOT T,et al.Outcomes of allogeneic transplantation after hypomethylating agents with venetoclax in acute myeloid leukemia［J］.Am J Hematol,2022,97(6):E191-E194.
［29］TENOLD ME,MOSKOFF BN,BENJAMIN DJ,et al.Outcomes of adults with relapsed/refractory acute myeloid leukemia treated with venetoclax plus hypomethylating agents at a comprehensive cancer center［J］.Front Oncol,2021,11:649209.
［30］BEWERSDORF JP,DERKACH A,GOWDA L,et al.Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant［J］.Leuk Lymphoma,2021,62(14):3394-3401.
［31］WU X,ZHANG J,CHEN Q,et al.Efficacy of venetoclax in combination with azacitidine followed by haploidentical transplantation in refractory acute myeloid leukaemia and mixed phenotype acute leukaemia［J］.Br J Haematol,2020,189(5):e200-e204.
［32］ZAPPASODI P,BROCINER M,MERATI G,et al.Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients［J］.Ann Hematol,2021,100(4):1111-1113.
［33］SHORT NJ,VENUGOPAL S,QIAO W,et al.Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure［J］.J Hematol Oncol,2022,15(1):12.
［34］BANG SY,PARK S,KWAG D,et al.A Successful bridge therapy combining hypomethylating agents with venetoclax for adult patients with newly diagnosed or relapsed/refractory acute myeloid leukemia［J］.Cancers (Basel),2023,15(6):1666.
［35］CAO XY,CHEN JQ,WANG H,et al.Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AML［J］.Ann Med,2023,55(1):388-400.
［36］WEI Y,XIONG X,LI X,et al.Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome［J］.Cancer Sci,2021,112(9):3636-3644.
［37］SCHULER E,WAGNER-DROUET EM,AJIB S,et al.Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group［J］.Ann Hematol,2021,100(4):959-968.
［38］ALDOSS I,YANG D,PILLAI R,et al.Association of leukemia genetics with response to venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia［J］.Am J Hematol,2019,94(10):E253-E255.
［39］BEJAR R,LORD A,STEVENSON K,et al.TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients［J］.Blood,2014,124(17):2705-2712.
［40］TRAINA F,VISCONTE V,ELSON P,et al.Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms［J］.Leukemia,2014,28(1):78-87.
［41］ZHAO P,NI M,MA D,et al.Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation［J］.Ann Hematol,2022,101(1):119-130.
［42］SHATILOVA A,BUDAEVA I,MOTORIN D,et al.AML-396 venetoclax-containing regimens improve outcomes of intensive treatment and allogeneic hematopoietic stem cell transplantation in patients with extramedullary acute myeloid leukemia［J］.Clin Lymphoma Myeloma Leuk,2022,22 Suppl 2:S246.
［43］MOUKALLED NM,EL DARSA H,HAIBE Y,et al.Feasibility of Venetoclax-based combinations for adult patients with acute myeloid leukemia relapsing after allogenic stem cell transplantation［J］.Bone Marrow Transplant,2019,54(4):620-624.
［44］CHEN Z,ZHEN S,ZHANG T,et al.Venetoclax plus hypomethylating agents versus intensive chemotherapy for hematological relapse of myeloid malignancies after allo-HSCT［J］.Front Oncol,2023,13:1137175.
［45］GAUT D,BURKENROAD A,DUONG T,et al.Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia:A single institution experience［J］.Leuk Res,2020,90:106314.
［46］ANDREANI G,DRAGANI M,SERRA A,et al.Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation［J］.Am J Hematol,2019,94(2):E48-E50.